123 related articles for article (PubMed ID: 38150668)
1. A Tumor-Specific Cascade-Activating Smart Prodrug System for Enhanced Targeted Therapy.
Wang Q; Jin D; Liu C; Shi L; Li T
Small; 2024 Jun; 20(24):e2309482. PubMed ID: 38150668
[TBL] [Abstract][Full Text] [Related]
2. A tumor-specific ROS self-supply enhanced cascade-responsive prodrug activation nanosystem for amplified chemotherapy against multidrug-resistant tumors.
Wang J; Zhang H; Lv J; Zheng Y; Li M; Yang G; Wei X; Li N; Huang H; Li T; Qin X; Li S; Wu C; Zhang W; Liu Y; Yang H
Acta Biomater; 2023 Jul; 164():522-537. PubMed ID: 37072069
[TBL] [Abstract][Full Text] [Related]
3. Dual-prodrug cascade activation for chemo/chemodynamic mutually beneficial combination cancer therapy.
Zhang X; Guo H; Zhang X; Shi X; Yu P; Jia S; Cao C; Wang S; Chang J
Biomater Sci; 2023 Jan; 11(3):1066-1074. PubMed ID: 36562486
[TBL] [Abstract][Full Text] [Related]
4. ROS-triggered cycle amplification effect: A prodrug activation nanoamplifier for tumor-specific therapy.
Huang Z; Ding Y; Luo Y; Chen M; Zeng Z; Zhang T; Sun Y; Huang Y; Zhao C
Acta Biomater; 2022 Oct; 152():367-379. PubMed ID: 36084924
[TBL] [Abstract][Full Text] [Related]
5. Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency.
Li W; Fu J; Ding Y; Liu D; Jia N; Chen D; Hu H
Acta Biomater; 2019 Sep; 96():456-467. PubMed ID: 31260821
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers.
Jin Y; Wang Y; Liu X; Zhou J; Wang X; Feng H; Liu H
Drug Des Devel Ther; 2020; 14():5205-5215. PubMed ID: 33268983
[TBL] [Abstract][Full Text] [Related]
7. Self-Distinguishing and Stimulus-Responsive Carrier-Free Theranostic Nanoagents for Imaging-Guided Chemo-Photothermal Therapy in Small-Cell Lung Cancer.
Zhu Q; Fan Z; Zuo W; Chen Y; Hou Z; Zhu X
ACS Appl Mater Interfaces; 2020 Nov; 12(46):51314-51328. PubMed ID: 33156622
[TBL] [Abstract][Full Text] [Related]
8. Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy.
Santra S; Kaittanis C; Santiesteban OJ; Perez JM
J Am Chem Soc; 2011 Oct; 133(41):16680-8. PubMed ID: 21910482
[TBL] [Abstract][Full Text] [Related]
9. Dual stimuli-responsive dendronized prodrug derived from poly(oligo-(ethylene glycol) methacrylate)-based copolymers for enhanced anti-cancer therapeutic effect.
Luo Q; Lin L; Huang Q; Duan Z; Gu L; Zhang H; Gu Z; Gong Q; Luo K
Acta Biomater; 2022 Apr; 143():320-332. PubMed ID: 35235863
[TBL] [Abstract][Full Text] [Related]
10.
Dong Y; Du P; Liu P
Int J Pharm; 2020 Oct; 588():119723. PubMed ID: 32755688
[TBL] [Abstract][Full Text] [Related]
11. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy.
Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X
Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753
[TBL] [Abstract][Full Text] [Related]
12. Reduction-Responsive Chemo-Capsule-Based Prodrug Nanogel for Synergistic Treatment of Tumor Chemotherapy.
Lu Y; Jia D; Ma X; Liang M; Hou S; Qiu W; Gao Y; Xue P; Kang Y; Xu Z
ACS Appl Mater Interfaces; 2021 Feb; 13(7):8940-8951. PubMed ID: 33565847
[TBL] [Abstract][Full Text] [Related]
13. EGFR-targeted prodrug activation using bioorthogonal alkene-azide click-and-release chemistry.
Fairhall JM; Camilli JC; Gibson BH; Hook S; Gamble AB
Bioorg Med Chem; 2021 Sep; 46():116361. PubMed ID: 34411983
[TBL] [Abstract][Full Text] [Related]
14. A bottlebrush-architectured dextran polyprodrug as an acidity-responsive vector for enhanced chemotherapy efficiency.
Zhang T; Wang Y; Ma X; Hou C; Lv S; Jia D; Lu Y; Xue P; Kang Y; Xu Z
Biomater Sci; 2020 Jan; 8(1):473-484. PubMed ID: 31755481
[TBL] [Abstract][Full Text] [Related]
15. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
16. A Dual-Mechanism Targeted Bioorthogonal Prodrug Therapy.
Yao Q; Lin F; Lu C; Zhang R; Xu H; Hu X; Wu Z; Gao Y; Chen PR
Bioconjug Chem; 2023 Dec; 34(12):2255-2262. PubMed ID: 37955377
[TBL] [Abstract][Full Text] [Related]
17. Modular Nanoparticulate Prodrug Design Enables Efficient Treatment of Solid Tumors Using Bioorthogonal Activation.
Miller MA; Mikula H; Luthria G; Li R; Kronister S; Prytyskach M; Kohler RH; Mitchison T; Weissleder R
ACS Nano; 2018 Dec; 12(12):12814-12826. PubMed ID: 30550257
[TBL] [Abstract][Full Text] [Related]
18. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
[TBL] [Abstract][Full Text] [Related]
19. Stimuli-responsive polymer-doxorubicin conjugate: Antitumor mechanism and potential as nano-prodrug.
Chen K; Cai H; Zhang H; Zhu H; Gu Z; Gong Q; Luo K
Acta Biomater; 2019 Jan; 84():339-355. PubMed ID: 30503561
[TBL] [Abstract][Full Text] [Related]
20. Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery.
Xu M; Qian J; Liu X; Liu T; Wang H
Mater Sci Eng C Mater Biol Appl; 2015 May; 50():341-7. PubMed ID: 25746279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
